SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References

The combination of lamivudine and hepatitis B immunoglobulin (HBIG) reduces the risk of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, the efficacy of this strategy and the need for combined therapy with adefovir dipivoxil (ADV) in patients who select lamivudine-resistant strains (YMDD) before surgery is still unknown. Twenty-two patients treated with lamivudine (LAM) who underwent LT after YMDD-mutant selection were studied. In 13 patients, YMDD mutants were associated with an HBV DNA breakthrough greater than 5 log10 (group A: phenotypic resistance), and 11 were treated with ADV to decrease viral load before LT. In the remaining 9 patients who did not experience the viral breakthrough, YMDD mutants were detected only retrospectively in sera stored at the time of LT (group B: genotypic resistance). During 35 months of post-LT follow-up, none of the 11 patients of group A treated with ADV before and after surgery (in addition to HBIG and LAM) had HBV recurrence, and neither did any of the 7 subjects of group B treated with LAM before and after transplantation (in addition to HBIG). HBV recurred in 2 patients of group A (untreated with ADV before surgery and transplanted with an HBV DNA exceeding 5 log10) and in 2 subjects of group B (who spontaneously stopped HBIG after surgery). In carriers of YMDD mutants, the risk of post-LT HBV recurrence is low, provided that preemptive and prophylactic ADV (in addition to LAM and HBIG) treatment is used in highly viremic patients and prophylactic LAM (or ADV) and HBIG therapy is continued in low viremic patients. (Liver Transpl 2005;11:532–538.)

In hepatitis B virus (HBV) DNA-positive patients, the rate of HBV recurrence after liver transplantation (LT) remains significant (50%–90%) despite monoprophylaxis with hepatitis B immunoglobulins (HBIG) or with lamivudine (LAM). In both cases, post-LT HBV recurrence may be associated with the appearance of viral mutants selected by either HBIG or LAM, whose occurrence appears correlated with the serum levels of HBV DNA at the time of LT.1–4

Resistance to LAM is characterized by the substitution of methionine with valine or isoleucine at residue 204 (formerly 552) within the tyrosine-methionine–aspartate-aspartate (YMDD) motif of the viral DNA polymerase. This mutation results in a more than 10,000-fold decrease in sensitivity to LAM treatment in vitro.5

The clinical lack of virologic response to LAM associated with the YMDD mutants is currently defined by a viral breakthrough with HBV DNA greater than 5 log10 copies/mL.6, 7 In the transplant setting, the appearance of the YMDD mutant during posttransplantation LAM prophylaxis is frequently associated with recurrence of the hepatitis B surface antigen (HBsAg) and liver disease in the graft.3

Although combined prophylaxis with LAM and HBIG is effective in preventing HBV recurrence after LT,8–14 whether it is equally effective in transplant candidates who have developed YMDD mutants before transplantation is not clear. Data for transplant recipients carrying the YMDD mutant at the time of surgery are few and contradictory. In two studies,13, 14 the presence of a LAM-resistant HBV DNA in serum at the time of transplantation was reported to predict post-LT viral recurrence despite HBIG and LAM prophylaxis. Conversely, combined LAM and HBIG prophylaxis prevented the clinical recurrence in a single highly viremic YMDD-positive patient for more than 32 months of follow-up.15 In another report, HBIG and LAM prophylaxis was effective in a YMDD carrier who experienced subacute liver failure, although data on HBV DNA load at the time of transplantation were unknown.16

In the process of the development of LAM resistance, genotypic resistance (YMDD detection without a significant HBV DNA breakthrough) frequently precedes the phenotypic resistance.17, 18 YMDD mutants can now be successfully treated with alternative drugs, such as adefovir dipivoxil (ADV), which appears to be effective against both wild-type and LAM-resistant HBV strains.19, 20 ADV has been shown to be able to control HBV recurrence after LT in a few case reports.21–23 However, the need for ADV therapy (before or after transplantation) as a prevention of hepatitis B recurrence is still debated, and data are lacking, especially when the differences of genotypic or phenotypic resistance to LAM are taken into account. In two recent studies,24, 25 pretransplantation ADV therapy improved the virologic, biochemical, and clinical parameters while patients were waiting for a new liver, even though data on post-LT HBV recurrence were not analyzed.

In this study, we analyzed a retrospective consecutive series of 22 HBsAg-positive patients with cirrhosis who developed YMDD mutation while on LAM therapy before LT, with particular reference to the additional use of ADV in combination with the current strategy for prevention of HBV recurrence after transplantation.

Patients and Methods

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References

Between 1997 and 2002, 99 patients with HBV-related cirrhosis underwent preemptive LAM treatment while waiting for LT in 2 Northern Italian liver transplantation centers: Molinette Hospital in Turin and National Cancer Institute in Milan. Patients were enlisted because of end-stage liver disease with or without hepatocellular carcinoma.

At listing, before any antiviral therapy, all patients had a viral load of more than 5 log10 copies/mL by a nonamplified assay7 and were treated with LAM (GlaxoWellcome, Greenford, UK) at an oral dose of 100 mg daily, to decrease the HBV DNA level before LT and to ameliorate liver function.

Study Population

During pretransplantation LAM therapy, 13 of 99 patients had a rebound of serum HBV DNA to levels greater than 5 log10 copies/mL and alanine-aminotransferase (ALT) levels greater than 1.5 times the upper limit of normal (YMDD-positive group A, phenotypic resistance). Eleven patients (cases 3–13) were suspended from the active waiting list at the moment of the virologic breakthrough until the ADV 10 mg/daily was added to LAM as rescue compassionate-use protocol (Gilead Sciences, Foster City, CA, GS-98-435 Study). As soon as HBV DNA levels fell below 5 log10 copies/mL, patients were relisted to LT and treated with triple prophylaxis (ADV, LAM, HBIG) in the posttransplantation follow-up (Table 1). The remaining 2 patients (cases 1 and 2) continued only LAM before surgery, because of the unavailability of ADV while on the waiting list, and underwent LT. After liver replacement, both patients received only a double prophylaxis (LAM and HBIG).

Table 1. Demographic and Clinical Features in YMDD Carriers at the Time of Mutant Detection
Patient no.AgeSexHCCPre-LAM HBV DNAHBeAg*Months of LAM before YMDD detectionHBV DNA load at YMDD detectionINNO-LiPA pattern 180/204/207
  • Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HBeA, hepatitis B e antigen; LAM, lamivudine. In the INNO-LiPA pattern column: w, wild-type; M, mutation in the reported position.

  • *

    HBeAg status did not change during both therapy with LAM and adefovir.

  • Log10 copies/mL; Amplicor HBV, COBAS Monitor, Roche.

  • Viral load was measured retrospectively on sera stored at the time of liver transplantation.

Group A
155MYes9.2Pos117.3MMw
251MYes8.8Neg88.8MMw
341MNo8.7Pos447.4MMM
447MYes7.3Pos139.0MMM
528FNo6.5Neg136.7MMw
648MYes7.6Neg276.9wMw
754MYes7.4Pos277.3MMw
856MYes7.1Neg507.3MMw
952MYes7.3Pos486.5MMw
1049FNo8.3Neg205.7wMw
1148FNo7.7Neg206.2wMw
1251MNo7.5Neg265.8wMw
1352MYes8.6Pos249.0MMw
Group B
1451MYes8.9Neg74.0wMw
1539MYes6.2Neg82.5wMw
1654MYes8.1Neg293.2wMw
1749MNo8.6Neg262.4wMw
1845MNo9.6Neg223.7MMw
1948MNo5.4Neg142.7MMw
2054MYes8.4Neg173.2wMw
2146MNo7.0Neg62.4wMw
2258MYes4.2Pos52.4MMw

Of the remaining 86 patients who did not experience the viral breakthrough and who underwent LT with HBV DNA levels less than 5 log10 copies/mL, a frozen serum sample collected at the time of surgery was retrospectively tested for HBV DNA by polymerase chain reaction (PCR) and INNO-LiPA assays. Seventy-seven patients had undetectable HBV DNA or had a viral load between 2.3 and 4 log10 copies/mL but wild-type sequence at the YMDD motif (YMDD-negative group), whereas 9 had detectable HBV DNA and LAM-resistant strains. These 9 patients (YMDD-positive group B, genotypic resistance) received LAM and HBIG after transplantation. During follow-up, 2 noncompliant patients (case numbers 14 and 15) stopped HBIG on their own initiative and decided to continue just LAM orally.

Overall, 22 patients with LAM resistance (YMDD-positive) were studied: 13 with phenotypic (group A) and 9 with genotypic (group B) resistance. In each patient of the series, detection of mutation in position 204 of the polymerase gene was confirmed, with various associations with mutations in positions 180 and 207 (Table 1).

In this group, 21 cadaveric and 1 living related liver transplantations were performed. There were 3 female patients and 19 male patients; the mean age was 49 years (range, 28–58 years). Seven patients were HBeAg positive (46% of group A subjects) and 15 had antibodies to the HBeAg (anti-HBe) (89% of group B subjects). All were negative for antibodies to HDV and only 1 (case 17) was positive for anti-hepatitis C antibodies; in 13 patients, hepatocellular carcinoma was confirmed by histology in the explanted cirrhotic liver. Before starting LAM, the mean viral load was comparable in both groups (7.8 log10 in group A and 7.4 log10 in group B, respectively) but phenotypic resistance developed more frequently in patients treated for a longer time with LAM (mean time of treatment, 25.5 months in group A and 15 months in group B, respectively) (Tables 1 and 2).

Table 2. HBV Recurrence in Lamivudine-Resistant Carriers (YMDD) in Relation to the Antiviral Therapy Before Surgery and to the Type of Prophylaxis After Liver Transplantation
Patient no.Before LTAfter LT
Antiviral therapy*Days of adefovirALT at time of LTHBV DNA at time of LT*Post-LT prophylaxisHBV recurrenceFollow-up mos after LT
  • Abbreviations: ALT, alanine aminotransferase. In the Antiviral therapy column: L, lamivudine; A, adefovir.

  • *

    Log10 copies/mL: Amplicor HBV, COBAS Monitor, Roche.

  • Group A: phenotypic resistance; Group B: genotypic resistance.

  • Therapy before liver transplantation (LT) and after LT prophylaxis: lamivudine (L), adefovir (A), anti–hepatitis B immunoglobulins (H).

  • Two patients received post-LT lamivudine, adefovir, and anti–hepatitis B immunoglobulins for approximately 1 month and then continued only with lamivudine and anti–hepatitis B immunoglobulins.

  • Viral load was measured retrospectively on sera stored at the time of LT.

  • #

    Two noncompliant patients suspended anti–hepatitis B immunoglobulins after LT.

Group A
1L0209.0LHYes34
2L0629.0LHYes29
3LA9047<2.3LAHNo33
4LA85184.5LHNo43
5LA451424.1LHNo64
6LA90744.6LAHNo35
7LA200264.7LAHNo21
8LA111484.2LAHNo22
9LA311176.0LAHNo19
10LA130473.4LAHNo19
11LA145214.0LAHNo27
12LA15024<2.3LAHNo21
13LA180594.5LAHNo16
Group B
14L0344.0LH [RIGHTWARDS ARROW] L#Yes73
15L0182.5LH [RIGHTWARDS ARROW] L#Yes41
16L0263.2LHNo26
17L0302.4LHNo26
18L0473.7LHNo23
19L0432.7LHNo59
20L0183.2LHNo87
21L0382.4LHNo33
22L0402.4LHNo18

HBIG Prophylaxis

In both LT centers, a mean total dose of 50,000 IU of intravenous HBIG (Hepatect, Biotest, Dreieich, Germany; VenBig, Kedrion, Barga, Italy) was administered during the first month, in an aim to produce anti-HBs titers in the serum greater than 500 IU/L. After hospital discharge and during the entire course of follow-up, each patient received a mean of 6,000 IU of intravenous HBIG every month, with the aim of keeping anti-HBs titers above 100 IU/L.

Immunosuppressive Regimen

After transplantation, a double-drug induction therapy with cyclosporine (CsA) and steroids was used. Steroids were tapered from day 0 to day 5 at 25 mg/day and discontinued 3 to 6 months after transplantation. Tacrolimus was introduced as a rescue therapy for steroid-resistant rejection or in case of CsA toxicity.

Assays and Definition

Liver function and serologic tests were measured with conventional assays (AUSRIA II and HBe Kit; Abbott Laboratories, North Chicago, IL; AB AUK 3, Sorin Biomedica, Saluggia, VC, Italy; Ortho Diagnostic System, Milano, Italy). Before starting LAM or ADV, all patients tested positive for HBV DNA by a nonamplified assay (Digene Hybrid-Capture II; Digene Corp., Gaithersburg, MD LLQ 0.5 pg/mL or 141,500 copies/mL) or branched DNA signal amplification (Bayer Corp., Tarrytown, NY, LLQ 700,000 Eq/mL).

During therapy and at the time of transplantation HBV DNA was detected using a quantitative PCR commercial assay, whose lower limit of detection is 200 copies/mL (2.3 log10 copies/mL) (Amplicor HBV, COBAS Monitor, Roche, Basel, Switzerland). In patients HBV DNA–positive by PCR at the time of transplantation, LAM-resistant mutants were tested with INNO-LiPA HBV DR (Innogenetics Inc., Ghent, Belgium). Recurrence of HBV was defined as the reappearance of HBsAg in serum at any time interval after liver replacement.

Results

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References

YMDD-Negative Group

After LT, the 77 patients in the YMDD-negative group were followed for a median of 39 months. Three patients (4%) died without evidence of HBV recurrence at 4, 12, and 30 months after surgery. Overall, HBV relapse occurred in 4 patients (5%) while on HBIG and LAM prophylaxis without evidence of YMDD selection at the time of hepatitis B recurrence.

YMDD-Positive Group

All 22 patients in the YMDD-positive group survived transplant surgery and were discharged from the hospital after a median of 17 days. One patient in group B (case number 17) died 20 months after LT from a massive bleeding after a liver biopsy without evidence of HBV recurrence. His follow-up was censored at the time of death. The current study focuses on the outcome of HBV infection, with special reference to pretransplantation and posttransplantation treatment.

Pretransplantation Outcome

Group A (Phenotypic Resistance)

In the 11 patients with phenotypic resistance to LAM who were treated with ADV while awaiting transplantation, the antiviral therapy was well tolerated (Table 2). In particular, renal side effects and consequent dose reduction were not registered although most of the transplant candidates suffered liver insufficiency. During 114 days (range, 31–200) of ADV treatment the mean Child-Turcotte-Pugh score did not change significantly, and HBV DNA decreased on average from 6.9 (range, 5.7–9.0) to 4.2 log10 copies/mL (range, <2.3–6.0), with a median decrease of 2.6 log10 copies/mL (range, 0.5–5.1). At transplantation, all patients but 1 (case 9) achieved an HBV DNA below 5 log10 copies/mL. As reported previously, 2 cases with phenotypic resistance to LAM arrived at transplantation with HBV DNA levels greater than 5 log10 copies/mL, because ADV was not available during the pretransplantation period.

Group B (Genotypic Resistance)

In the 9 patients who were retrospectively identified as carriers of genotypic YMDD mutants, HBV DNA levels ranged from 2.4 to 4.0 log10 copies/mL (median, 2.9) at transplantation.

Posttransplantation Outcome

The median posttransplantation follow-up for the entire series was 35 months (range, 16–87) (Table 2 and Fig. 1). Overall, HBV recurrence was detected in 4 YMDD carriers: 2 subjects in the group A and 2 in the group B; differences are discussed in the following sections.

thumbnail image

Figure 1. Posttransplantation outcome of 22 YMDD carriers, according to pretransplantation hepatitis B virus (HBV) DNA levels and antiviral therapy. In carriers of YMDD mutants, the risk of posttransplantation HBV recurrence is low, provided that preemptive and prophylactic adefovir dipivoxil (ADV) (in addition to lamivudine [LAM] and hepatitis B immunoglobulin [HBIG]) treatment is used in highly viremic patients, and prophylactic LAM and HBIG therapy is continued in low viremic patients.

Download figure to PowerPoint

Group A (Phenotypic Resistance)

Patients were followed for a median of 29 months (range, 16–64) after LT. The 2 patients who suffered HBV recurrence during this period underwent transplantation in the presence of high serum levels of HBV DNA (9 log10 copies/mL) as a result of YMDD mutants and did not receive ADV before or after LT but received LAM and HBIG combination therapy after surgery. HBV recurred within the first 2 months after LT in both patients, featuring a fibrosing cholestatic hepatitis in 1.

Conversely, none of the 11 patients treated with ADV before and after LT showed any sign of HBV recurrence during follow-up. Nine patients received triple prophylactic therapy (ADV, LAM, HBIG) throughout the follow-up, whereas in 2 patients (case numbers 4 and 5), ADV was stopped 3 and 32 days after LT for primary liver malfunction and renal failure and psychiatric side effects, respectively. It is noteworthy that combined HBIG and LAM prophylaxis was effective in preventing HBV recurrence in these 2 patients.

Group B (Genotypic Resistance)

Patients were followed for a median of 43 months after LT (range, 18–87). HBV recurred in the 2 patients who decided to stop HBIG on their own initiative and remained on LAM monoprophylaxis 4 and 3 months after surgery. In these patients, HBV DNA at the time of surgery was detectable only by PCR with an HBV DNA level of 2.5 and 4.0 log10 copies/mL. The remaining 7 patients receiving a posttransplantation prophylaxis with LAM and HBIG did not show any clinical/biochemical sign of HBV recurrence throughout the entire follow-up.

Clinical Outcome After Liver Transplantation

Patients who did not experience the HBV recurrence after LT remained persistently HBsAg negative without any biochemical or clinical evidence of HBV, whereas all 4 subjects who experienced recurrence had a clinical and histologic profile of chronic HBV. After the HBV recurrence, 3 patients stopped HBIG, continued LAM, and added ADV.

Discussion

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References

The protective effect of LAM prophylaxis on post-LT HBV recurrence is not complete in viremic patients, and its loss of efficacy is frequently associated with the selection of YMDD resistant mutants.1–3 The use of post-LT combination therapy with passive immunoprophylaxis (HBIG) and LAM also reduces the rate of HBV recurrence in viremic subjects, because these drugs act synergistically on HBV replication.8–14

Pre-LT YMDD mutant selection can pose an increased risk of HBV recurrence, related to a possible inefficacy of the prophylactic combination therapy15, 16; however, the effects of the viral load at the time of LT and, consequently, of the genotypic versus the phenotypic resistance17, 18 on the rate of recurrence or the need for ADV therapy in addition either before or after LT, are still not clear.

In this study, a correlation between HBeAg positivity (indicating a higher viral fitness), duration of LAM therapy, and phenotypic resistance was confirmed, in accordance with previous reports.2, 3 However, a low risk of HBV recurrence was observed in patients with genotypic resistance (group B) who underwent transplantation with a viral load of less than 5 log10 copies/mL and who were treated, after surgery, with a combined prophylaxis of HBIG and LAM. By contrast, both patients with phenotypic resistance (group A) who selected YMDD mutants with a significant virologic breakthrough of greater than 5 log10 copies/mL before LT and not treated with ADV before LT developed HBV recurrence while on LAM and HBIG prophylaxis.

The lack of the protective effect of combined prophylaxis with HBIG and LAM in highly viremic patients confirms that in YMDD carriers, the synergistic efficacy of combination is directly related to the viral load at the time of LT, in agreement with reports from Germany.13, 14 By contrast, the level of viremia at the time of transplantation was not relevant in both patients with genotypic resistance who stopped HBIG after LT. In this setting, the HBV recurrence was related to the discontinuation of HBIG and to the maintenance of LAM monoprophylaxis in presence of the YMDD variant, as previously described.2

The characteristics of the study, as a retrospective uncontrolled clinical trial, do not allow definitive conclusions but give some indication of the association of antiviral(s) and immunoprophylaxis after LT in YMDD carriers. In this setting, further controlled studies are needed to define the most appropriate prophylaxis regimen (a double or a triple prophylaxis), but the prevalence of YMDD variants in these patients could favor the use of ADV in LT candidates and the addition of ADV to HBIG after LT both in genotypic and phenotypic YMDD resistance.

The very low frequency of escape mutants associated with ADV therapy and the risk of hepatitis flares leading to decompensation of cirrhosis after YMDD mutants selection could suggest that ADV should replace LAM for antiviral therapy before LT in all viremic patients listed. However, in this setting the role of LAM remains important, in our opinion, because the faster antiviral effect of LAM is effective in patients with cirrhosis (± hepatocellular carcinoma) who need an LT in an acceptable (6–12 months) timeframe, while a careful virologic monitoring and ADV addition in case of YMDD selection can prevent hepatitis flares, virologic breakthroughs, and a new risk of post-LT recurrence.

In conclusion, this study confirms the importance of a dynamic virologic analysis in HBsAg carriers treated with LAM both before and after LT. In these patients, the majority of HBV recurrences are highly preventable by using combined prophylaxis with HBIG and LAM, but preemptive therapy with LAM before LT can select resistant mutants.

Conventional combined prophylaxis with LAM and HBIG for prevention of HBV recurrence maintains its efficacy in YMDD genotypic resistance when HBV DNA levels remain below 5 log10 copies/mL. Thus, these patients should not be removed from the waiting list but could require ADV addition in relation to the risk of a significant viral relapse during further follow-up on the waiting list. The risk of recurrence becomes very high with LAM monoprophylaxis, and this regimen or HBIG discontinuation must be avoided in the presence of YMDD at the time of transplantation. In these patients, the use of ADV and HBIG after LT could be justified by the baseline presence of the LAM-resistant variant. However, when YMDD carriers develop a virologic breakthrough before LT (phenotypic resistance), the risk of recurrence during the conventional combined prophylaxis with HBIG and LAM becomes very high, but the use of ADV before LT aimed to reduce the viral load associated with HBIG after surgery permits the control of HBV recurrence.

References

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References
  • 1
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18421847.
  • 2
    Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, et al. High pre-treatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30: 715721.
  • 3
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107113.
  • 4
    Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213222.
  • 5
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine clinical investigation group. Hepatology 1998; 27: 16701677.
  • 6
    EASL international consensus conference on hepatitis B. J Hepatol 2003; 38: 533540.
  • 7
    Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003; 38: S90S103.
  • 8
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence after liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585589.
  • 9
    Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999, 5: 491496.
  • 10
    Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 6: 520525.
  • 11
    McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 6: 512519.
  • 12
    Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence in cirrhotic patients treated with lamivudine before surgery and combined with passive immunoprophylaxis after liver transplantation. J Hepatol 2001; 34: 903910.
  • 13
    Rosenau J, Bahr MJ, Tilmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B infection after liver transplantation: possible role of mutations in the YMDD motif before transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895902.
  • 14
    Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 15281535.
  • 15
    Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RWl. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119: 13821384.
  • 16
    Starkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J, Lerut J. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure because of the emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001; 35: 679681.
  • 17
    Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003; 98: 151159.
    Direct Link:
  • 18
    Gaia S, Marzano A, Smedile A, Barbon V, Abate M, Olivero A, et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2004; 20: 281287.
  • 19
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808816.
  • 20
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800807.
  • 21
    Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 19121914.
  • 22
    Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, et al. Adefovir dipivoxil for treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129134.
  • 23
    Marzano A, Ciancio A, Salizzoni M, Rizzetto M, Negro F. Hepatitis B virus subtypes and lamivudine resistance. Lancet 2001; 358: 153154.
  • 24
    Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 14191427.
  • 25
    Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.